Additionally, some treatments target the CCL2–CCR2 axis to improve muscle pathology in dystrophinopathy by decreasing the accumulation of monocytes/macrocytes [43, 44, 53], which can potentially affect the homing of CCR2-ADSCs. Here, CCL2 is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.